ribosomal protein L36 pseudogene 19Genealiases: []
Q-omics provides the consensus-scored RPL36P19 profile across patient tissues and cancer cell-line models. RPL36P19 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL36P19 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, RPL36P19 RNA expression shows 12,695 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where RPL36P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36P19 survival associations across molecular data types. RPL36P19 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36P19 RNA expression–survival associations across cancer types. High RPL36P19 expression shows unfavorable associations in UVM, THCA, SKCM, BLCA and PCPG, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL36P19 RNA expression.
This table summarizes RPL36P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36P19 shows lower tumor expression in KIRC and higher tumor expression in LUSC. The KIRC box plot shows higher RPL36P19 RNA expression in normal versus tumor tissue (log2 FC = −0.043, t-test p = .014).
This table shows molecular features associated with RPL36P19 in patient tissues and cancer cell lines. In patient samples, RPL36P19 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
